67
Participants
Start Date
August 10, 2011
Primary Completion Date
February 27, 2012
Study Completion Date
July 3, 2012
Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)
One dose will be administered intramuscularly at Study Day 0.
GSK Biologicals' malaria vaccine 257049 (2 doses)
Two doses will be administered intramuscularly at monthly intervals
GSK Biologicals' malaria vaccine 257049 (3 doses)
Three doses will be administered intramuscularly at monthly intervals
Sporozoite challenge
Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
GSK Investigational Site, Silver Spring
Lead Sponsor
The PATH Malaria Vaccine Initiative (MVI)
OTHER
Crucell Holland BV
INDUSTRY
GlaxoSmithKline
INDUSTRY